Cartesian Therapeutics (RNAC) Other Non-Current Assets (2015 - 2026)

Cartesian Therapeutics (RNAC) has 11 years of Other Non-Current Assets data on file, last reported at $1.7 million in Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 3.95% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 3.95% increase from a year earlier, with the FY2025 full-year figure at $1.7 million, up 234.94% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $1.7 million, roughly flat from $1.7 million in the prior quarter.
• Over the last five years, Other Non-Current Assets for RNAC reached as high as $5.6 million in Q2 2025 and fell as low as $518000.0 in Q4 2024.
• Historically, Other Non-Current Assets has averaged $1.9 million across 5 years, with a median of $1.6 million in 2022.
• Across the five-year window, Other Non-Current Assets tumbled 62.38% in 2024 and jumped 234.94% in 2025, its largest moves.
• Year by year, Other Non-Current Assets stood at $1.6 million in 2022, then retreated by 13.94% to $1.4 million in 2023, then tumbled by 62.38% to $518000.0 in 2024, then soared by 234.94% to $1.7 million in 2025, then changed by 0.0% to $1.7 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Assets figures were $1.7 million in Q1 2026, $1.7 million in Q4 2025, and $5.6 million in Q3 2025.